Expression and role of Foxa proteins in prostate cancer.
The molecular mechanism(s) for prostate cancer progression to androgen independence are poorly understood. We have recently shown that Foxa1 and Foxa2 proteins are differentially expressed in epithelial cells during murine prostate development, growth, and adult function. Currently, the role of Foxa proteins in prostate cancer development and progression is unknown. Foxa protein expression was investigated in the LPB-Tag LADY mouse prostate cancer models, in human prostate cancer specimens, and various prostate cancer cell lines using Western blot and immunostaining analysis. In vitro transient transfection, studies were performed to investigate Foxa/prostate-specific gene regulation. Foxa1 was strongly expressed in areas of prostatic intraepithelial neoplasia (PIN) in both the androgen dependent 12T-7f and in the metastatic, androgen independent 12T-10 LADY models. Prominent Foxa1 and Foxa2 expression was observed in 12T-10 invasive undifferentiated neuroendocrine carcinomas, in the hormone independent and metastasizing 12T-10 derived, NE-10 allograft tumors, and in all metastatic lesions isolated from 12T-10 mice. Foxa1 protein expression was always observed in human prostate carcinomas, regardless of Gleason grade score, while Foxa2 was only detected in neuroendocrine small cell carcinomas and in some high Gleason score adenocarcinomas. Foxa proteins were also differentially expressed in three prostate cancer cell lines. Importantly, in vitro functional assays demonstrated that Foxa2 could activate androgen-dependent prostate-specific genes in an androgen receptor and ligand-independent manner. These results suggest that Foxa proteins are important in prostate carcinogenesis. In particular, Foxa2 may be involved in progression of prostate cancer to androgen independence. As such, Foxa proteins may represent novel targets for therapeutic intervention.
Mirosevich
Janni
J
Vanderbilt Prostate Cancer Center, AA-1302 Medical Center North, Nashville, Tennessee 37232-2765, USA.
Gao
Nan
N
Gupta
Aparna
A
Shappell
Scott B
SB
Jove
Richard
R
Matusik
Robert J
RJ
D000230:Adenocarcinoma / Q000737:chemistry / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D000728:Androgens / Q000502:physiology; D000818:Animals; D018278:Carcinoma, Neuroendocrine / Q000737:chemistry / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D018288:Carcinoma, Small Cell / Q000737:chemistry / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D018450:Disease Progression; D004848:Epithelium / Q000737:chemistry / Q000473:pathology / Q000503:physiopathology; D005455:Fluorescent Antibody Technique; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology*; D051541:Hepatocyte Nuclear Factor 3-alpha / Q000032:analysis / Q000235:genetics / Q000502:physiology*; D051542:Hepatocyte Nuclear Factor 3-beta / Q000032:analysis / Q000235:genetics / Q000502:physiology*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D019048:Prostatic Intraepithelial Neoplasia / Q000737:chemistry / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D011471:Prostatic Neoplasms / Q000737:chemistry / Q000235:genetics / Q000473:pathology / Q000503:physiopathology*; D014162:Transfection; D015854:Up-Regulation
D000728:Androgens; C496499:FOXA1 protein, human; C496502:FOXA2 protein, human; C496500:Foxa1 protein, mouse; C496503:Foxa2 protein, mouse; D051541:Hepatocyte Nuclear Factor 3-alpha; D051542:Hepatocyte Nuclear Factor 3-beta